TScan Therapeutics, Inc. (TCRX): Total Liabilities
$105.67M
As of 2025-12-31
$102.43M
As of 2026-06-30
+2.0%
3-year compound annual growth
+26.6%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $105.67M | -18.8% | 2026-03-04, Balance as of period end |
| 2024-12-31 | $130.15M | +7.3% | 2026-03-04, Balance as of period end |
| 2023-12-31 | $121.28M | +21.7% | 2025-03-05, Balance as of period end |
| 2022-12-31 | $99.66M | +264.7% | 2024-03-06, Balance as of period end |
| 2021-12-31 | $27.33M | -16.0% | 2023-03-08, Balance as of period end |
| 2020-12-31 | $32.52M | n/a | 2022-03-09, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $105.67M | -18.8% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $17.20M | +47.7% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $96.38M | +8.5% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $53.19M | -11.9% |
| Curis Inc (CRIS) | 2025-12-31 | $14.50M | -69.3% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $69.24M | +91.2% |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $54.27M | -42.0% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $91.52M | n/m |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $64.95M | +69.7% |
Compare TCRX, ACOG, TSHA, CRBU side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗